Dr. Henry is a Distinguished Professor at the University of Arkansas in Biological Sciences and the Institute for Nano-scale Science and Engineering. His research is focused on protein targeting, protein production technologies, and development of protein therapies to treat methamphetamine addiction. Henry is a co-founder and VP Biopharmaceutics at InterveXion Therapeutics where his efforts support interactions with FDA, manufacturing and testing of InterveXion’s protein therapies, and oversight of these therapies in human clinical trials. Patents resulting from his work support InterveXion (intervexion.com)and another Arkansas-based start-up, Boston Mountain Biotech (mtnbio.com). Dr. Henry holds the WM Keck Professorship in Biological Sciences.